Testing of the Akt/PKB Inhibitor MK-2206 by the Pediatric Preclinical Testing Program

BACKGROUND: MK-2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer. PROCEDURES: MK-2206 was tested against the PPTP in vitro panel using a 96 hour exposure (1.0 nM-10 μM), and in vivo using thrice weekly dosing for a planned 4 weeks at...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gorlick, Richard, Maris, John M., Houghton, Peter J., Lock, Richard, Carol, Hernan, Kurmasheva, Raushan T., Kolb, E. Anders, Keir, Stephen T., Reynolds, C. Patrick, Kang, Min H., Billups, Catherine A., Smith, Malcolm A.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3290691/
https://ncbi.nlm.nih.gov/pubmed/22102563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.23412
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars